SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 2
    American Lung Association. Available at: http://www.lungusa.org./atf/cf Accessed October 1, 2005.
  • 3
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 1995; 311: 899909.
  • 4
    Bunn PAJr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why. J Clin Oncol. 2002; 20: 23s33s.
  • 5
    Johnson DH. Targeted therapy in non-small cell lung cancer: myth or reality Lung Cancer. 2003; 41: S3S8.
  • 6
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123132.
  • 7
    Sandler AB, Gray R, Brahmer J, et al. Randomized Phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group trial: E4599. J Clin Oncol. 2005; 23(16S): 2s. Abstract LBA 4.
  • 8
    Solit DB, Morris M, Slovin S, et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003; 98: 18421848.
  • 9
    Veeder MH, Jett JR, Su JQ, et al. A Phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992; 70: 22812287.
  • 10
    Castro M, Veeder MH, Mailliard JA, et al. A prospective study of pulmonary function in patients receiving mitomycin C. Chest. 1996; 109: 939944.
  • 11
    Goldberg RM, Jett JR, Therneau TM, et al. Bolus versus infusional etoposide and cisplatinum in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment Group. J Natl Cancer Inst. 1990; 82: 18991903.
  • 12
    Gesme DHJr., Jett JR, Schreffler DD, et al. A randomized Phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer: a trial of the North Central Cancer Treatment Group. Cancer. 1993; 71: 27232726.
  • 13
    Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol. 1994; 12: 11261129.
  • 14
    Weitz JJ, Marschke RF, Sloan JA, et al. A randomized Phase II trial of 2 schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer. 2000; 28: 157162.
  • 15
    Colon-Otero G, Niedringhous RD, Hillman SH, et al. A Phase II trial of edatrexate, vinblastine, Adriamycin, cisplatin and filgrastim (EVAC/G-CSF) in patients with advanced non-small cell carcinoma of the lungs: a NCCTG trial. Am J Clin Oncol (CCT). 2001; 24: 551555.
  • 16
    Perez EA, Amin BR, Hillman SL, et al. Randomized Phase II study of docetaxel and gemcitabine for Stage IIIB/IV non-small cell lung cancer. Lung Cancer. In press.
  • 17
    Ma CX, Nair S, Thomas S, et al. Pemetrexed and gemcitabine as front-line therapy for advanced NSCLC: a randomized, Phase II NCCTG trial of three schedules. J Clin Oncol. 2005; 23: 59295937.
  • 18
    Kelly K, Crowley J, Bunn PJr., et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 32103218.
  • 19
    Center for Disease Prevention. Available at: http://www.cdc.gov/nccdphp/dnpa/bmi/bmi-means.htm Accessed October 1, 2005.
  • 20
    Grambsh PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515526.
  • 21
    Harrell FEJr., Lee KL, Mark DB. Tutorial in biostatistics multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361387.
  • 22
    Harrell FE, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984; 3: 143152.
  • 23
    Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell. Lung cancer: a decade of progress. Chest. 2002; 122: 10371057.
  • 24
    Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell-lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol. 2005; 23: 175183.
  • 25
    Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991; 9: 16181626.
  • 26
    Takigawa N, Segawa Y, Okahara M, et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer. 1996; 15: 6777.
  • 27
    Watine J. Further comments on “A practical prognostic index for inoperable non-small-cell lung cancer”: a clinical biologist's point of view. J Cancer Res Clin Oncol. 1998; 124: 581583.
  • 28
    Wigren T. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol. 1997; 44: 915.
  • 29
    Paesman M, Sculier JP, Libert P et al. Prognostic factors for survival in advanced non-small lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol. 1995; 13: 12211230.
  • 30
    Ferrigno D, Buccheri G. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis. 2003; 59: 193198.
  • 31
    Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for Stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004; 22: 17971806.